Surrozen, Inc. (SRZN) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Sarozen corporate update conference call. My name is Josh and I will be your manager for this call. I will now turn the call over to Craig Parker, CEO of Sarozen to begin the call. Thanks, Josh. And thank all of you for joining us today for this important corporate update. As Josh said, I'm Craig Parker, CEO of Sarozen. And with me today is Chuck Williams, the chief financial officer at Sarozen. We'll be providing corporate and R&D pipeline updates today, and we'll then address questions. Slide two. I'll be making forward-looking statements. Please consult our SEC filings, in particular our 2022 annual report on Form 10-K for a full discussion of our risk factors. Slide three. As some of you know, Surizin is the preeminent innovator in using the Wnt pathway, the body's own physiologic mechanism for tissue repair, to selectively stimulate tissue regeneration in a broad range of diseases. We do this through our proprietary platform and technologies that combine an understanding of Wnt pathway biology in specific disease settings with advanced antibody engineering techniques and proprietary antibody technologies. Our vision is to design and develop tissue-selective antibodies that have the potential to regenerate tissue in many severe diseases. It's this targeted approach to Wnt modulation and the extremely broad potential therapeutic applications that distinguish our approach and our technologies. The ultimate clinical promise of our approach is disease-modifying benefit. Wnt signaling plays an essential role in regulating many biological processes, including regenerative responses to tissue injury, and we see myriad opportunities to regenerate tissue for clinical benefit. We've invented several novel multivalent antibody-based approac...